Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices: A Single-Center Randomized Controlled Trial

NCT07352228 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT07352228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07352228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices: A Single-Center Randomized Controlled Trial
Lead sponsor
Xijing Hospital
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
January 1, 2026
Completion date
October 30, 2028
Enrollment
350 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carvedilol, propranolol, rebleeding of portal hypertension in liver cirrhosis